Logo do repositório
 
Publicação

Preclinical evaluation of asparagus stipularis in a rat model of metabolic syndrome and development of its nanoencapsulated form

2026-06-02Artigo científico Acesso aberto
Ver registo simples
datacite.subject.sdg03:Saúde de Qualidade
datacite.subject.sdg09:Indústria, Inovação e Infraestruturas
datacite.subject.sdg12:Produção e Consumo Sustentáveis
dc.contributor.authorAdouni, Khaoula
dc.contributor.authorZouaoui, Olfa
dc.contributor.authorBrandão, Pedro
dc.contributor.authorRijo, Patrícia
dc.contributor.authorLima, Sofia A. Costa
dc.contributor.authorReis, Salette
dc.contributor.authorAchour, Lotfi
dc.contributor.authorFonte, Pedro
dc.date.accessioned2026-06-30T16:50:56Z
dc.date.available2026-06-30T16:50:56Z
dc.date.issued2026-06-02
dc.description.abstractContext: Asparagus stipularis Forssk decoction (ASD) has shown potential metabolic and antioxidant benefits, yet its effects on pancreatic dysfunction associated with metabolic syndrome remain insufficiently explored. Objective: The aim of this work was to assess the pancreatic protective properties of ASD in high-fructose diet (HFrD)-fed rats and to characterize ASD-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) as a delivery system to enhance its therapeutic potential. Methods: Rats were fed an HFrD and treated with ASD at two dose levels. Serum α-amylase and lipase activities were measured to assess digestive enzyme modulation. Pancreatic lipid peroxidation was quantified using thiobarbituric acid reactive substances (TBARS), while antioxidant enzyme activities, including superoxide dismutase, catalase, and glutathione peroxidase, were determined. Histopathological examination was performed to evaluate structural alterations in pancreatic tissues. ASD was encapsulated into PLGA NPs, and particle size, polydispersity index (PdI), zeta potential (ZP), and encapsulation efficiency (EE) were analyzed. Results: ASD significantly reduced serum α-amylase activity to 2285.3 ± 256.6U/L (low dose) and 1846.4 ± 82.8U/L (high dose) compared to HFrD controls. Serum lipase activity decreased by 13% and 18% at the respective doses. TBARS levels were markedly reduced, and antioxidant enzyme activities were restored to near-control levels. Histological analysis revealed improved β-cell morphology and reduced acinar degeneration. ASD-loaded PLGA NPs exhibited a mean size of 248 ± 5nm, PdI of 0.13 ± 0.01, ZP of −24.7 ± 1.3mV, and an EE of 75.5 ± 3.2%. Conclusion: ASD demonstrates significant pancreatic protective effects, and nanoencapsulation enhances its therapeutic promise for metabolic disorders.eng
dc.description.sponsorshipUID/04326/2025; UID/PRR/04326/2025; UID/04565/2025
dc.identifier.doi10.1080/03639045.2026.2674218
dc.identifier.eissn1520-5762
dc.identifier.issn0363-9045
dc.identifier.urihttp://hdl.handle.net/10400.1/29179
dc.language.isoeng
dc.peerreviewedyes
dc.publisherTaylor and Francis Group
dc.relationCentre for Marine and Environmental Research
dc.relationEgas Moniz Interdisciplinary Research Center
dc.relation.ispartofDrug Development and Industrial Pharmacy
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectAsparagus stipularis
dc.subjectα‐amylase
dc.subjectPancreatic lipase
dc.subjectHigh-fructose diet
dc.subjectOxidative stress
dc.subjectPLGA nanoparticles
dc.titlePreclinical evaluation of asparagus stipularis in a rat model of metabolic syndrome and development of its nanoencapsulated formeng
dc.typejournal article
dspace.entity.typePublication
oaire.awardNumberLA/P/0101/2020
oaire.awardNumberUIDB/04585/2020
oaire.awardTitleCentre for Marine and Environmental Research
oaire.awardTitleEgas Moniz Interdisciplinary Research Center
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/LA%2FP%2F0101%2F2020/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB%2F04585%2F2020/PT
oaire.citation.endPage1390
oaire.citation.issue7
oaire.citation.startPage1377
oaire.citation.titleDrug Development and Industrial Pharmacy
oaire.citation.volume52
oaire.fundingStream6817 - DCRRNI ID
oaire.fundingStream6817 - DCRRNI ID
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85
person.familyNameFonte
person.givenNamePedro
person.identifier.ciencia-id2410-123D-3385
person.identifier.orcid0000-0002-1115-9282
person.identifier.ridK-3215-2013
person.identifier.scopus-author-id55146900200
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
relation.isAuthorOfPublicationa5a5c2b2-9112-4bf4-8618-8c2051bbc116
relation.isAuthorOfPublication.latestForDiscoverya5a5c2b2-9112-4bf4-8618-8c2051bbc116
relation.isProjectOfPublication794d4c77-c731-471e-bc96-5a41dcd3d872
relation.isProjectOfPublication2cd937f3-d3f3-44e6-9fdf-534d27a28b2c
relation.isProjectOfPublication.latestForDiscovery794d4c77-c731-471e-bc96-5a41dcd3d872

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Preclinical evaluation of Asparagus stipularis in a rat model of metabolic syndrome and development of its nanoencapsulated form.pdf
Tamanho:
6.05 MB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
3.46 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

CCM2-Artigos (em revistas ou actas indexadas)
FCT2-Artigos (em revistas ou actas indexadas)